10-KPeriod: FY2024

QUEST DIAGNOSTICS INC Annual Report, Year Ended Dec 31, 2024

Filed February 20, 2025For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) reported fiscal year 2024 revenues of $9.9 billion. The company operates as a leading provider of diagnostic information services, serving approximately one-third of the adult U.S. population annually. Their strategy focuses on growth and operational efficiency, driven by an industry-leading test menu, collaborations with healthcare providers, leveraging data assets for population health, and embracing innovative technologies like AI and automation. Significant strategic initiatives include expanding Advanced Diagnostics™ capabilities, particularly in molecular genomics and oncology, exemplified by the acquisition of Haystack Oncology. Quest Diagnostics also emphasizes consumer-centric services through platforms like QuestHealth.com and aims to partner with hospitals to improve laboratory operations. The company actively manages capital through acquisitions, dividends, and share repurchases, demonstrating a commitment to returning value to stockholders. They also highlight a strong focus on quality improvement, operational efficiency through programs like 'Invigorate', and maintaining strong relationships with health plans and other payers.

Financial Highlights

55 data points
Beta

Revenue

$9.87B

32.9% Gross Margin

Net Income

$871.00M

8.8% Net Margin

EPS (Diluted)

$7.69

Total Assets

$16.15B

Cash & Equivalents

$549.00M

Free Cash Flow

$909.00M

Financial Statements
Beta
Revenue$9.87B
Cost of Revenue$6.63B
Gross Profit$3.24B
SG&A Expenses$1.77B
Operating Expenses$8.53B
Operating Income$1.35B
Net Income$871.00M
EPS (Basic)$7.78
EPS (Diluted)$7.69
Shares Outstanding (Basic)111.00M
Shares Outstanding (Diluted)113.00M

Key Highlights

  • 1Quest Diagnostics reported $9.9 billion in net revenues for fiscal year 2024.
  • 2The company serves approximately one-third of the adult U.S. population annually, leveraging a vast database of de-identified clinical lab results.
  • 3Strategic focus includes growth through an expanded test menu, Advanced Diagnostics (especially in oncology and genomics), and partnerships.
  • 4Significant investments in innovation include leveraging Artificial Intelligence (AI) and automation to improve efficiency and diagnostic capabilities.
  • 5The company executed significant acquisitions in 2024, including Allina Health, OhioHealth, University Hospitals outreach businesses, and LifeLabs Inc., totaling $2.2 billion.
  • 6Quest Diagnostics is committed to returning value to shareholders through dividends (with a recent 6.7% increase) and share repurchases.
  • 7The company emphasizes continuous quality improvement and operational efficiency, supported by initiatives like the 'Quest Management System' and 'Invigorate' cost-saving program.

Frequently Asked Questions

Quest Diagnostics reported $9.9 billion in net revenues for fiscal year 2024. The company continues to be a major player in the diagnostic information services market, serving a significant portion of the U.S. adult population. Their strategic focus remains on growth, driven by innovation, an expanded test menu, and advanced diagnostics, alongside operational efficiency improvements.

Quest Diagnostics is investing in future growth through several avenues. They are expanding their Advanced Diagnostics offerings, particularly in molecular genomics and oncology, and leveraging technologies like Artificial Intelligence (AI) and automation to enhance services and operational efficiency. Strategic acquisitions, such as LifeLabs Inc., also play a key role in their growth strategy.

Quest Diagnostics follows a disciplined capital deployment framework. This includes strategic acquisitions, investments in the business, and returning capital to stockholders through dividends and share repurchases. The company recently announced an increase in its quarterly cash dividend, demonstrating a commitment to consistent shareholder returns.

Key risks for Quest Diagnostics include the evolving U.S. healthcare system and changing market fundamentals, intense competition, government and private payer reimbursement pressures (including PAMA and value-based care shifts), regulatory changes (like FDA's approach to LDTs), cybersecurity threats, and potential disruptions from new technologies. Failure to adapt to these factors could materially impact the company's performance.